Skye Bioscience Investors Face Jan. 16 Deadline in Securities Class Action

Overview

• Notices from Rosen Law Firm, Levi & Korsinsky, and Berger Montague highlight a court deadline of January 16, 2026 for investors to move to be appointed lead plaintiff.
• The suit covers purchasers of Skye securities from November 4, 2024 through October 3, 2025 and seeks to recover investor losses.
• The complaint alleges Skye overstated the effectiveness and prospects of its lead candidate, nimacimab, rendering public statements misleading.
• A Berger Montague notice says investors learned negative details on October 6, 2025 when topline Phase 2a data reportedly showed nimacimab missed its primary weight-loss endpoint, after which the stock fell about 60% to $1.90.
• No class has been certified, and firms state investors may participate through contingency arrangements with no upfront fees.